Dublin, Ireland, 2 April 2008 - AGI Therapeutics plc (“AGI” or the “Company”) (AIM, IEX: AGI), a speciality pharmaceutical company focused on gastrointestinal drug products, today announces the key findings of a clinical study to assess the pharmacokinetic profile of arbaclofen (AGI-006), which is being developed for the treatment of gastroparesis, a significant gastric condition amongst diabetics.
